Literature DB >> 7573354

Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma.

C M Mooy1, G P Luyten, P T de Jong, T M Luider, T Stijnen, F van de Ham, C C van Vroonhoven, F T Bosman.   

Abstract

Neoplasia can be defined as deregulated tissue homeostasis caused by an imbalance between proliferation and apoptosis. Many genes are involved in the maintenance of tissue homeostasis, eg, the c-myc oncoprotein, which is an important regulator of cell proliferation and Bcl-2 protein, which is involved in the regulation of apoptosis. We studied retrospectively indices of proliferation, such as mitotic count and the Mib-1 index, on 51 uveal melanomas and compared their prognostic significance with established indicators of prognosis such as cell type and tumor size. Along the same line we investigated the expression of the regulating proteins c-myc and Bcl-2. Of all parameters tested, the largest tumor diameter and mitotic count were most strongly associated with tumor-related death (P < 0.001 and P = 0.005, respectively). In addition, cell type, the presence of epithelioid cells, the Mib-1 index, and the percentage of cytoplasmic c-myc-positive cells were significant predictive factors. Multivariate analysis showed that the Mib-1 index, largest tumor diameter, and the percentage of cytoplasmic c-myc-positive cells were independent prognostic parameters. Bcl-2 expression did not correlate with clinical outcome. The Mib-1 index correlated with the presence of epithelioid cells (P < 0.03) and the presence of apoptotic bodies (P < 0.001) and c-myc. A strong inverse relationship was found between (nuclear and cytoplasmic) c-myc and Bcl-2 (P < 0.00004 and P < 0.006, respectively), suggesting that Bcl-2 cooperates with c-myc to immortalize uveal melanoma cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573354      PMCID: PMC1871011     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

Review 1.  BCL-2: physiology and role in neoplasia.

Authors:  A Bagg; J Cossman
Journal:  Cancer Treat Res       Date:  1992

2.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

Authors:  T J McDonnell; P Troncoso; S M Brisbay; C Logothetis; L W Chung; J T Hsieh; S M Tu; M L Campbell
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

Review 3.  Molecular themes in oncogenesis.

Authors:  J M Bishop
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

4.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes.

Authors:  A Fanidi; E A Harrington; G I Evan
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

5.  Apoptotic cell death induced by c-myc is inhibited by bcl-2.

Authors:  R P Bissonnette; F Echeverri; A Mahboubi; D R Green
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

6.  Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma.

Authors:  Q L Lu; G Elia; S Lucas; J A Thomas
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

7.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

8.  C-myc oncogene expression in ocular melanomas.

Authors:  J A Royds; R M Sharrard; M A Parsons; J Lawry; R Rees; D Cottam; B Wagner; I G Rennie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

9.  Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin.

Authors:  J C Reed; L Meister; S Tanaka; M Cuddy; S Yum; C Geyer; D Pleasure
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

Review 10.  Apoptosis (the 1992 Frank Rose Memorial Lecture).

Authors:  A H Wyllie
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

View more
  9 in total

1.  Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas.

Authors:  C Chiquet; J D Grange; L Ayzac; P Chauvel; L M Patricot; M Devouassoux-Shisheboran
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.

Authors:  J S Chana; G D Wilson; I A Cree; R A Alexander; N Myatt; M Neale; A J Foss; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

3.  Orthotopic human choroidal melanoma xenografts in nude rats with aggressive and nonaggressive PAS staining patterns.

Authors:  Rod D Braun; Asad Abbas
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

4.  Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; Edson J Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

5.  Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.

Authors:  S E Coupland; N Bechrakis; A Schüler; I Anagnostopoulos; M Hummel; N Bornfeld; H Stein
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

6.  Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.

Authors:  Fariba Némati; Catherine de Montrion; Guillaume Lang; Laurence Kraus-Berthier; Guillaume Carita; Xavier Sastre-Garau; Aurélie Berniard; David Vallerand; Olivier Geneste; Ludmilla de Plater; Alain Pierré; Brian Lockhart; Laurence Desjardins; Sophie Piperno-Neumann; Stéphane Depil; Didier Decaudin
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

Review 7.  Uveal melanoma: estimating prognosis.

Authors:  Swathi Kaliki; Carol L Shields; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

8.  p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma.

Authors:  Raheela Awais; David G Spiller; Michael R H White; Luminita Paraoan
Journal:  Br J Cancer       Date:  2016-09-01       Impact factor: 7.640

9.  A novel combinatorial treatment option for metastatic uveal melanoma.

Authors:  Alik Honigman; Shahar Frenkel; Dudi Shneor; Shay Tayeb; Jacob Pe'er; Hanna Voropaev; Maria Gimmelshein; Nathalie Cassoux
Journal:  Oncotarget       Date:  2018-05-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.